KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) FCF Margin (2016 - 2026)

NovoCure's FCF Margin history spans 13 years, with the latest figure at 10.73% for Q1 2026.

  • On a quarterly basis, FCF Margin rose 1913.0% to 10.73% in Q1 2026 year-over-year; TTM through Mar 2026 was 7.13%, a 448.0% increase, with the full-year FY2025 number at 11.55%, down 11.0% from a year prior.
  • FCF Margin hit 10.73% in Q1 2026 for NovoCure, up from 13.13% in the prior quarter.
  • Over the last five years, FCF Margin for NVCR hit a ceiling of 12.76% in Q3 2022 and a floor of 31.3% in Q1 2024.
  • Historically, FCF Margin has averaged 10.5% across 5 years, with a median of 10.73% in 2026.
  • Biggest five-year swings in FCF Margin: tumbled -3363bps in 2023 and later soared 2067bps in 2024.
  • Tracing NVCR's FCF Margin over 5 years: stood at 7.89% in 2022, then crashed by -102bps to 15.98% in 2023, then soared by 52bps to 7.68% in 2024, then crashed by -71bps to 13.13% in 2025, then increased by 18bps to 10.73% in 2026.
  • Business Quant data shows FCF Margin for NVCR at 10.73% in Q1 2026, 13.13% in Q4 2025, and 8.92% in Q3 2025.